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Abstract
The morphogen Sonic hedgehog (Shh) holds great promise for repair or regeneration of tissues suffering ischemic injury,
however clinical translation is limited by its short half-life in the body. Here, we describe a coacervate delivery system which
incorporates Shh, protects it from degradation, and sustains its release for at least 3 weeks. Shh released from the
coacervate stimulates cardiac fibroblasts to upregulate the expression of multiple trophic factors including VEGF, SDF-1a,
IGF-1, and Shh itself, for at least 48 hours. Shh coacervate also demonstrates cytoprotective effects for cardiomyocytes in a
hydrogen peroxide-induced oxidative stress environment. In each of these studies the bioactivity of the Shh coacervate is
enhanced compared to free Shh. These results warrant further investigation of the in vivo efficacy of Shh coacervate for
cardiac repair.
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Introduction
Heart failure afflicts 5.7 million Americans, a prevalence that is
expected to rise 25% by 2030 [1]. There is an urgent need for
preventative and regenerative therapies for this deadly disease, for
which current treatments only seek to slow its progression [2]. The
best therapy may involve ‘‘master switch’’ agents which activate
multiple downstream pathways [3]. Sonic hedgehog (Shh) is one
such master regulator, acting as a powerful morphogen during
development when it typically influences cell fate but can also
affect cell growth and survival [4,5]. Shh signaling remains active
in the adult mammalian heart at very low levels though it is
upregulated during ischemic heart injury such as myocardial
infarction (MI) and congestive heart failure [6,7]. Currently,
damage to the adult heart is considered permanent as cardiomy-
ocytes have limited proliferative capability and fibrosis occurs post-
MI instead of healing [2,8]. However, during development, when
cardiac tissue patterning is controlled by powerful morphogens
such as Shh [9], the embryonic mammalian heart briefly displays
the ability to regenerate itself [10]. Temporarily recapitulating this
embryonic signaling environment through exogenous application
of cardiac morphogen Shh is therefore a possible approach
towards repair of the damaged adult heart.
Shh has previously been applied to the heart as a free protein.
Direct injection has been shown to restore blood flow in a critical
hindlimb ischemia model [11]. However, this approach is highly
inefficient due to short morphogen half-lives in the body [12] and
therefore requires multiple injections. High dosage is also
necessary to elicit a desired effect which is expensive and may
carry similar safety concerns to gene therapy. Investigations using
gene therapy [7,13] and transduced cell therapy [14] have been
shown to improve cardiac function following MI. However, both
of these approaches carry high risk of inducing tumor formation,
especially considering the potency of morphogens [15], and thus
trials have not progressed beyond large animal models. On the
contrary, a controlled delivery approach provides stabilization and
protection of Shh and can release it slowly to maintain a constant
local concentration within the therapeutic range.
Here we introduce a controlled delivery system comprised of
heparin and a synthetic polycation that interact polyvalently and
phase separate from water to form sub-micron sized spherical
droplets. These emulsion-like aggregations are referred to as a
‘‘coacervate’’. Shh is incorporated into the coacervate by high-
affinity binding to heparin and is then released in a slow and
sustained fashion. We demonstrate that Shh delivered by the
coacervate can have multiple beneficial effects on cardiac cells,
stimulating trophic factor expression and affording cytoprotection
from oxidative stress, and may therefore have the potential to
protect the heart from ischemia or promote tissue regeneration
following insult. This is, to the best of our knowledge, the first
investigation of controlled delivery of Shh for cardiac repair.
Materials and Methods
Ethics statement
Animals were cared for in compliance with a protocol approved
by the Institutional Animal Care and Use Committee of the
University of Pittsburgh, following NIH guidelines for the care and
use of laboratory animals (NIH publication No. 85–23 rev. 1985).
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Shh coacervate preparation
Poly(ethylene argininylaspartate diglyceride) (PEAD) was syn-
thesized as previously described [16]. PEAD and clinical-grade
heparin (Scientific Protein Labs, Waunakee, WI) were each
dissolved in 0.9% saline at 10 mg ml21 and 0.22 mm filter-
sterilized. Heparin was initially complexed with recombinant
mouse Shh (N-terminus peptide; R&D Systems, Minneapolis,
MN), then PEAD was added. Self-assembly of PEAD and
heparin:Shh immediately precipitated the ternary complex out
of solution to form the Shh coacervate.
Shh coacervate imaging
Shh was fluorescently labeled using Alexa Fluor 488 Protein
Labeling Kit (Invitrogen, Carlsbad, CA). A fluorescently labeled
Shh coacervate was prepared in water with 0.2 ng fluorescently
labeled Shh, 100 mg heparin, and 500 mg PEAD. The coacervate
was added to a 96-well plate and imaged using an Eclipse Ti
inverted microscope (Nikon, Tokyo, Japan).
Shh release profile
200 ml Shh coacervate containing 10 mg heparin, 100 ng Shh,
and 50 mg PEAD was prepared in 0.9% sterile saline and was then
pelleted by centrifugation at 12,100 g for 5 min. The supernatant
was aspirated and stored at 280uC and 200 ml fresh saline was
replaced to cover the pellet. The sampling procedure was repeated
on day 1, 4, 7, 10, 14, and 21 for three separate tubes. Released
Shh in the fractions was quantified by DuoSet ELISA kit (R&D
Systems) according to the manufacturer’s instructions.
Cardiac cell isolation
Primary cardiac cells were isolated from 1–2 day old Sprague-
Dawley rat pups (Jackson Labs, Bar Harbor, ME). The pups’
hearts were excised aseptically and the Worthington Neonatal
Cardiomyocyte Isolation System (Worthington, Lakewood, NJ)
was used following the manufacturer’s instructions. Two pre-plates
of 1.5 h each were used to separate cardiac fibroblasts (fast-
adhering cells) from cardiomyocytes (slow-adhering cells). The
purified cardiomyocyte population was seeded into 24-well plates
coated with 1 mg cm22 fibronectin (Millipore, Billerica, MA) at
1.56105 myocytes per well for experiments. Cardiomyocytes were
cultured in DMEM/F12 50/50 supplemented with 5% fetal
bovine serum (FBS), ITS supplement (Sigma, St. Louis, MO), and
100 mM 5-bromo-29-deoxyuridine (BrdU; Sigma) to inhibit
proliferation of any remaining fibroblasts. Cardiac fibroblasts
from the first pre-plate were cultured in DMEM supplemented
with 10% FBS through 3 passages before use in experiments.
Immunofluorescent staining
Immediately after isolation, purity of cardiac cell populations
was analyzed by immunostaining using a mouse anti-myosin heavy
chain (MHC) antibody (1:80, Millipore) followed by goat anti-
mouse IgG Alexa Fluor 594-conjugated secondary antibody
(1:200, Invitrogen) and counterstained with DAPI. All images
were taken using an Eclipse Ti inverted microscope (Nikon).
Cardiac fibroblast growth factor signaling
Isolated neonatal rat cardiac fibroblasts were used at passage 4.
56104 cells were seeded per well in a 24-well plate and cultured to
90% confluency. Cells were then washed once with DPBS and
500 ml ‘‘stimulation media’’ containing 1 mg ml21 Shh free or in
the coacervate, or normal culture media was added. After 6, 12,
24, 48 h the conditioned media from two wells per group was
removed and frozen. Indirect ELISA was run using rabbit
polyclonal antibodies against VEGF (1:50, Peprotech, Rocky Hill,
NJ), SDF-1a (1:30, Santa Cruz Biotech, Santa Cruz, CA), and
IGF-1 (1:30, Santa Cruz Biotech). Results were normalized to total
protein content, determined using Pierce 660 nm Protein Assay
(Thermo Fisher Scientific, Waltham, MA). For Shh quantification,
western blot was employed with samples being denatured and
reduced. Lacking a well-accepted protein loading control for
conditioned media, total protein assay results were used to
determine appropriate loading volumes for each sample, such
that 47.5 mg protein was loaded to each well. Following transfer,
the PVDF membrane was incubated for 5 m in Ponceau-S
staining solution (Sigma), rinsed in DI water and imaged.
Immunoblotting was then performed using a rabbit anti-human
Shh polyclonal antibody (1:200, Santa Cruz Biotech) followed by a
peroxidase conjugated anti-rabbit IgG antibody (Sigma). Band
intensities were measured using NIH Image J Version 1.46r
software.
Cardiomyocyte oxidative stress-induced apoptosis
Isolated cardiomyocytes were cultured for 2 d after which cells
were spontaneously contracting at approximately 1 beat per
second. Cells were pre-treated for 48 h with 500 ng ml21 Shh or
recombinant human fibroblast growth factor-2 (FGF2; Peprotech)
as either free protein or delivered by the coacervate. The FGF2
coacervate was prepared similarly to the Shh coacervate. Cells
were then exposed to 200 mM H2O2 in serum-free media to
induce oxidative stress. Two control groups received no growth
factor pre-treatment and then one received H2O2 and one did not.
After 2 h, cells were harvested, lysed, and assayed using EnzChek
Caspase-3 Kit #2 (Invitrogen). Immediately before harvesting the
cardiomyocytes, videos were taken in the center of the wells using
an Eclipse Ti inverted microscope (Nikon) using standard light
microscopy settings.
Statistical analysis
Statistical analysis was performed using SPSS 16.0 software
(SPSS Inc, Chicago, IL). Data was tested for normality and equal
variance before analysis. Statistical differences between groups
were calculated using one-way analysis of variance (ANOVA)
followed by Tukey post-hoc testing. Differences were considered
significant at P,0.05.
Results
Shh coacervate characterization and release
Fluorescent imaging of the Shh coacervate revealed round
droplets ranging from 0.5–10 mm in size (Fig. 1). Shh release from
the coacervate into saline was sustained for at least 3 weeks with
80% being released in total (Fig. 2). Less than 5% Shh was
detected in the supernatant immediately after forming the
coacervate and pelleting, therefore loading efficiency is greater
than 95%. There was effectively no initial burst release. Of the
100 ng loaded, approximately 6 ng day21 was released until day
10, then slowing to around 2 ng day21 until day 21.
Shh coacervate upregulates growth factor secretion by
cardiac fibroblasts
Isolated neonatal rat cardiac fibroblasts were stimulated with
Shh, free or in the coacervate, and analyzed for expression of
various growth factors over 2 days. Shh itself was detected in
increasing concentrations, up to 7.8 times the initially added
amount by 48 h (Fig. 3a). VEGF, SDF-1a, and IGF-1 were at 2- to
4-fold higher levels by 6 hours after stimulation with both free Shh
and Shh coacervate and remained upregulated for 48 h (Fig. 3b–d).
Controlled Delivery of Shh for Cardiac Repair
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The VEGF level at the 6 hour timepoint stimulated by Shh
coacervate was significantly greater than that stimulated by free
Shh. Conditioned media from cells treated with normal culture
media had undetectable concentrations of all growth factors tested
at every timepoint (data not shown).
Shh coacervate protects cardiomyocytes from apoptosis
Caspase-3 is a well-known indicator of cell apoptosis due to
oxidative stress, mimicked here with 200 mM H2O2 in culture
media. This concentration of H2O2 is higher than has been
previously reported to induce myocyte apoptosis [17]. Cardiac cell
isolation yielded a highly pure population of primary neonatal rat
cardiomyocytes (Fig. S1). Myocytes pre-treated with FGF2
coacervate or Shh coacervate showed significantly lower levels of
apoptosis compared to the H2O2 treated control, but higher levels
than the control group not treated with H2O2 (Fig. 4). Addition-
ally, the difference in means compared to the H2O2 treated
control was more statistically significant for Shh coacervate than
for FGF2 coacervate (p = 0.003 vs. p = 0.012). Incubation with free
FGF2 or Shh did reduce caspase-3 levels, however these
differences were not statistically significant (p = 0.094 and
p= 0.083) from the H2O2 treated control. Videos taken at the
experiment endpoint show that cardiomyocytes were beating
normally in the non-H2O2 treated control (Video S1), but rapidly
and irregularly in the Free Shh group (Video S2) and Shh
coacervate group (Video S3). Additionally, more cells were beating
in the Shh coacervate group than in the Free Shh group in
accordance with our caspase-3 results.
Discussion
Ischemic damage to the heart may be mitigated by Shh through
three key mechanisms: i) Angiogenesis- the sprouting of new blood
vessels from pre-existing ones, ii) Cytoprotection of cardiomyo-
cytes under oxidative stress, and iii) Recruitment of cardiac
progenitor cells.
Shh-induced neovascularization is a result of upregulated
paracrine signaling by fibroblasts of several angiogenic factors
including vascular endothelial growth factor (VEGF) and angio-
poetin-1 [11,18,19]. It has also been shown to increase the
contribution of bone marrow-derived endothelial progenitor cells
(EPCs) to the neovascularization process [19–21]. Additionally,
recent reports have revealed that Shh acts through the Rho-
associated protein kinase (ROCK) pathway, rather than its
traditional Gli-dependent pathway, to stimulate expression of
matrix metalloproteinase-9 (MMP-9) and osteopontin (OPN) in
endothelial cells [22,23]. These multiple complex roles of Shh
underscore its importance in ischemic revascularization. In the
present work we show that the Shh coacervate can stimulate
cardiac fibroblasts to significantly upregulate expression of VEGF.
Furthermore, Shh coacervate acutely (6 hour timepoint) stimulat-
ed significantly more VEGF production than free Shh. This may
be attributed to enhanced morphogen bioactivity when delivered
by the coacervate, as discussed later. In vivo, this upregulated
angiogenic growth factor expression may induce angiogenesis to
re-vascularize the ischemic myocardium.
The cytoprotective effects Shh displays for cardiomyocytes have
also been attributed to multiple mechanisms. One contributor is
insulin-like growth factor (IGF-1) which has been shown to be
upregulated in Shh-stimulated cardiac fibroblasts [7] and bone
marrow-derived cells [24]. IGF-1 interferes with the transcription
of angiotensin II, thereby preventing the formation of reactive
oxygen species during oxidative stress [25,26]. A more direct anti-
apoptotic role of Shh has also been demonstrated in vitro for
cardiomyocytes, which express the Shh receptor Patched-1 [7].
Our results seem to confirm this direct role, as recombinant Shh
protein applied alone to stressed cardiomyocytes reduced cell
apoptosis. Yet we must still consider that the cardiomyocyte
population was not entirely pure and may have contained a small
number of fibroblasts. Upregulated secretion of IGF-1 by these
fibroblasts may have therefore played a role as well. FGF2 was
included as a positive control in apoptosis experiments as it is a
well-known survival factor for numerous cell types [27–29]
including cardiomyocytes [30], and we have experience delivering
it with the coacervate [31–33]. We observed the coacervate to
enhance the bioactivity of both FGF2 and Shh compared to either
Figure 1. Shh coacervate imaging. Alexa Fluor 488-labeled Shh was
incorporated into the coacervate in water and imaged by fluorescence
microscopy. (a) 106 magnification. (b) 406 magnification. Scale
bars = 100 mm.
doi:10.1371/journal.pone.0063075.g001
Figure 2. Shh release profile. In vitro release of Shh from the
coacervate into saline over 21 days, quantified by sandwich ELISA.
Percent release is relative to total amount loaded. Bars indicate means
6 SD.
doi:10.1371/journal.pone.0063075.g002
Controlled Delivery of Shh for Cardiac Repair
PLOS ONE | www.plosone.org 3 May 2013 | Volume 8 | Issue 5 | e63075
factor in free form. We also found that Shh coacervate protected
stressed cardiomyocytes better than FGF2 coacervate. This is
significant because FGF2 expression by fibroblasts has actually
been shown to be downregulated in response to Shh stimulation
[11]. The anti-apoptotic effects of Shh must therefore be ascribed
to non-FGF2-related pathways.
Stromal cell-derived factor-1 (SDF-1), also known as CXCL12,
is a trafficking chemokine for stem and progenitor cells [34]. It has
been shown to act in local recruitment of cardiac progenitor cells
[35–37], as well as EPCs [38] and smooth muscle progenitor cells
[39]. It is well accepted that SDF-1 plays a pivotal role in stem and
progenitor cell homing to sites of injury [40]. We prove here that
Shh coacervate can upregulate production of SDF-1a at least as
well as equal dose of free Shh, therefore the bioactivity of released
Shh is well maintained. In vivo, high local levels of SDF-1a may
encourage recruitment of blood derived EPCs to aid in
neovascularization, and of cardiac progenitor cells to engender
myocardial tissue repair.
Clearly, Shh acts as a ‘‘master switch’’ agent in many tissues
including the heart, activating multiple downstream pathways in
response to injury. Shh has been shown to activate the ERK1/2
[41], PKC [14], ROCK [22], and PI3K/Akt [20] signaling
pathways, among others. Shh morphogen may therefore provide
benefits similar to co-delivery of multiple different growth factors.
However, a multi-factor approach would require extensive
optimization of growth factor dosage and release rate, while Shh
stimulates a natural healing environment, similar to the embryonic
state when cardiac regeneration is possible. Finally, we also
observed upregulated Shh expression by cardiac fibroblasts in
response to stimulation with Shh, a positive autoregulation that
has been previously reported [7].
Regarding the role the coacervate plays in enhancing the effects
of Shh, we point to heparin as a major player. Proteoglycans
associated with the extracellular matrix or cell surface play a vital
role in the transduction of cell signaling pathways [42]. Heparin
binds many growth factors, cytokines, and morphgens, stabilizes
and protects them, and in some cases modulates their activity
[43,44]. It has been shown to interact with a growth factor
molecule and its corresponding cell receptor simultaneously,
forming a stable ternary complex which facilitates signal activation
[45]. Heparan sulfate proteoglycans have also been shown to play
Figure 3. Shh-stimulated cardiac fibroblast signaling. Near-confluent cardiac fibroblasts were incubated with Shh, free or in the coacervate,
and growth factor levels in the conditioned media were assessed after 6, 12, 24, and 48 h. Data is presented as a fold-change from the stimulation
media (C). Bars indicate means 6 SD. (a) Quantification of Shh concentration in the cardiac fibroblast-conditioned media by western blot. Ponceau-S
staining of protein bands near 27 kDa is shown as the loading control. (b) Quantification of VEGF in the cardiac fibroblast-conditioned media by
indirect ELISA, *P,0.05. (c) Quantification of SDF-1a in the cardiac fibroblast-conditioned media by indirect ELISA. (d) Quantification of IGF-1 in the
cardiac fibroblast-conditioned media by indirect ELISA.
doi:10.1371/journal.pone.0063075.g003
Figure 4. Cytoprotection of cardiomyocytes from oxidative
stress-induced apoptosis. Myocytes were pre-treated for 48 h with
FGF2 or Shh, free or delivered in the coacervate. Cells were then
exposed to oxidative stress conditions with H2O2 for 2 h. Two control
groups were not pre-treated with any growth factors and then one
received H2O2 for 2 h (+) and one did not (2). Cell apoptosis levels were
measured by caspase-3 activity. *P,0.05, **P,0.01 compared to the
+H2O2 control group.
doi:10.1371/journal.pone.0063075.g004
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a vital role in developmental patterning and specifically in
regulating Hedgehog distribution and pathway activation
[46,47]. Heparin binds Shh with high affinity (Kd = 99 nM) [48]
and may inherently enhance its bioactivity by mimicking the in situ
signaling environment. Indeed, the biological activity of Shh has
been shown to be directly related to its affinity for heparin [48].
We suggest that utilizing heparin in our delivery system may
thereby potentiate the activity of Shh. This is supported by our
previous reports using the coacervate to deliver FGF2 [32,33],
neuronal growth factor [31], and heparin-binding EGF-like
growth factor [49]. However, the efficacy of the coacervate at
maintaining or enhancing the bioactivity of Shh in an in vivo
environment requires further evaluation.
The activity of bound factors is further preserved within the
coacervate, which is in a separate phase from water. This isolation
provides further protection from proteases. The heparin:Shh
complex is soluble in water and if injected in vivo would therefore
be quickly diluted and removed from the injection site. To
maintain the complex locally, an insoluble coacervate is formed
using a synthetic polycation, PEAD. This ariginine-based polyca-
tion was designed to imitate the highly cationic heparin-binding
domain [45]. Heparin-bound factors are incorporated into the
coacervate and protected from proteolysis and denaturation.
Release from the coacervate is based on slow hydrolysis of the
polycation [16], as well as dissolution of the complex in an ionic
environment. We expect the release of Shh from the coacervate to
be accelerated in vivo in in the presence of enzymes. We have
previously shown this polycation to be highly biocompatible and to
complex with heparin to control the release of many different
growth factors [16]. The results presented here suggest that a
simple liquid coacervate has high potential as a system of
controlled delivery for heparin-binding morphogens, in addition
to growth factors.
Conclusions
The results of this study indicate that PEAD-heparin coacervate
can load Shh with high efficiency and sustain its release for at least
21 days. Shh released from the coacervate displays bioactivity
equal to or higher than that of free Shh. We demonstrate the
ability of Shh coacervate to protect cardiomyocytes from oxidative
stress and to upregulate secretion of multiple growth factors by
cardiac fibroblasts. These results warrant further investigation of
Shh coacervate for treating cardiac ischemia.
Supporting Information
Figure S1 Neonatal rat cardiac cell populations were
separated by pre-plate technique. Slow-adhering cardiomy-
ocytes did not adhere to the pre-plate while fast-adhering cardiac
fibroblasts did adhere. Both populations were immunofluorescent
stained for myosin heavy chain (MHC) muscle cell marker (red)
and counterstained with DAPI for cell nuclei (blue). Scale
bars = 100 mm.
(TIF)
Video S1 Cardiomyocytes in the – H2O2 control group
not receiving any Shh pre-treatment and not treated
with H2O2 in the apoptosis assay.
(WMV)
Video S2 Cardiomyocytes in the Free Shh group pre-
treated for 48 h with 500 ng ml21 free Shh protein and
then treated with H2O2 for 2 h in the apoptosis assay.
(WMV)
Video S3 Cardiomyocytes in the Shh coacervate group
pre-treated for 48 h with 500 ng ml21 Shh in the
coacervate and then treated with H2O2 for 2 h in the
apoptosis assay.
(WMV)
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